Wilson John J. Addington 4

What Happened

• John J. Addington, Chief Operating Officer of Rapid Micro Biosystems, was granted two equity awards on Feb 11, 2026: 74,000 restricted stock units (RSUs) and 147,000 derivative awards (options/other derivative securities). Both awards were reported as acquired at $0.00 (no cash exchanged).

Key Details

• Transaction date: Feb 11, 2026; filing posted Feb 13, 2026 (Form 4 accession 0001380106-26-000017).
• Award amounts and price: 74,000 RSUs @ $0.00; 147,000 derivative shares @ $0.00.
• Vesting (from filing footnotes):
  • RSUs: Vest in three annual installments — 33.4% on the first anniversary of the Feb 11, 2026 grant date, and 33.3% on each of the second and third anniversaries, subject to continued service.
  • Derivative award (option): Vests in 48 substantially equal monthly installments; first installment vests Mar 11, 2026.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Grant/Award; the 147,000 entry is listed as a derivative award. No 10b5-1 plan or tax-withholding sale noted in the provided notes.
• Filing timeliness: Report filed two days after the transaction date (appears timely under Form 4 rules).

Context

• These are compensation grants, not open-market purchases or sales. RSUs deliver shares upon vesting; the derivative award vests monthly (likely an option or other time‑vested equity) and must be exercised per its terms to deliver shares. No shares were sold or exercised in this filing, so there was no immediate cash transaction or disposition to signal buying/selling intent. Grants like these are common for executive pay and retention.